{"preliminary_commentary":{"by_channel":{"x_thread":11},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03801902\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-16T20:50:45.531Z","note":"Automated from the 10 newest of 11 indexed sources (Feb 2019 – Dec 2025). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":10,"text":"- Whether durvalumab with radiotherapy alone can match concurrent chemoradiotherapy followed by consolidation durvalumab\n- Whether accelerated hypofractionated radiotherapy with durvalumab performs as well as conventional fractionation\n- Whether high PD-L1 expression is a sufficient basis for omitting concurrent chemotherapy","kind":"questions"},"drugs_tested":[["monalizumab","durvalumab"],["oleclumab","durvalumab"],["durvalumab"]],"indication":"PD-L1 high locally advanced non-small cell lung cancer","name":"ARCHON-1","nct_id":"NCT03801902","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=archon-1-nct03801902. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Starting 2 weeks prior to radiation therapy, patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 4 weeks for 13 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo ACRT 1 fraction per day, 5 days per week for 15 fractions. Patients also undergo brain MRI or CT scan during screening and as clinically indicated, chest CT scans on study and during follow up, and collection of blood samples during screening and on study.","label":"Arm I (CLOSED) (Durvalumab and ACRT)","type":"EXPERIMENTAL"},{"description":"Starting 2 weeks prior to radiation therapy, patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 4 weeks for 13 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo conventionally fractionated radiation therapy 1 fraction per day, 5 days per week for 30 fractions. Patients also undergo brain MRI or CT scan during screening and as clinically indicated, chest CT scans on study and during follow up, and collection of blood samples during screening and on study.","label":"Arm II (CLOSED) (Durvalumab and standard RT)","type":"EXPERIMENTAL"},{"description":"Starting 2 weeks prior to radiation therapy, patients receive durvalumab IV over 60 minutes and monalizumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 4 weeks for 13 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo conventionally fractionated radiation therapy 1 fraction per day, 5 days per week for 30 fractions. Patients also undergo brain MRI or CT scan during screening and as clinically indicated, chest CT scans on study and during follow up, and collection of blood samples during screening and on study.","label":"Arm III (durvalumab, monalizumab, standard RT)","type":"EXPERIMENTAL"},{"description":"Starting 2 weeks prior to radiation therapy, patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Patients also receive oleclumab IV over 60 minutes on days 1 and 15 of cycles 1-2, then on day 1 of cycles thereafter. Treatment repeats every 4 weeks for 13 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo conventionally fractionated radiation therapy 1 fraction per day, 5 days per week for 30 fractions. Patients also undergo brain MRI or CT scan during screening and as clinically indicated, chest CT scans on study and during follow up, and collection of blood samples during screening and on study.","label":"Arm IV (durvalumab, oleclumab, standard RT)","type":"EXPERIMENTAL"}],"collaborators":["NRG Oncology"],"completion_date":{"date":"2025-09-04","type":"ACTUAL"},"conditions":["Locally Advanced Lung Non-Small Cell Carcinoma","Locally Recurrent Lung Non-Small Cell Carcinoma","Stage II Lung Cancer AJCC v8","Stage III Lung Cancer AJCC v8","Unresectable Lung Non-Small Cell Carcinoma"],"enrollment":{"count":26,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Accelerated Hypofractionated Radiation Therapy","otherNames":["AHF-RT","AHRT"],"type":"RADIATION"},{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Specimen Collection"],"type":"PROCEDURE"},{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","Diagnostic CAT Scan","Diagnostic CAT Scan Service Type","tomography"],"type":"PROCEDURE"},{"name":"Durvalumab","otherNames":["Imfinzi","Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer","MEDI 4736","MEDI-4736","MEDI4736"],"type":"BIOLOGICAL"},{"name":"Magnetic Resonance Imaging of the Brain with and without Contrast","otherNames":["Brain Magnetic Resonance Imaging with and without Contrast","Brain MRI","Brain MRI with and without Contrast","Head MRI with and without Contrast"],"type":"PROCEDURE"},{"name":"Monalizumab","otherNames":["Immunoglobulin G4-kappa, Anti-(Homo sapiens KLRC1 (Killer Cell Lectin-like Receptor Subfamily C Member 1, NKG2-a, NKG2a, CD159A, CD94)), Humanized Monoclonal Antibody","IPH-2201","IPH2201","NN-8765","NN8765","NN8765-3658"],"type":"BIOLOGICAL"},{"name":"Oleclumab","otherNames":["Anti-CD73 Monoclonal Antibody MEDI9447","MEDI9447"],"type":"BIOLOGICAL"},{"name":"Radiation Therapy","otherNames":["Cancer Radiotherapy","Energy Type","ENERGY_TYPE","Irradiate","Irradiated","Irradiation","Radiation","Radiation Therapy, NOS","Radiotherapeutics","Radiotherapy","RT","Therapy, Radiation"],"type":"RADIATION"}],"last_update":"2025-09-23","lead_sponsor":"National Cancer Institute (NCI)","official_title":"Phase I Trial of Radiotherapy Combined With Durvalumab Alone Plus Either Monalizumab or Oleclumab in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2021-10-26","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants Experiencing a Safety Event","timeFrame":"From start of study treatment to 90 (ACRT) or 56 (standard RT) days from the end of radiation treatment. (Approximately 104 or 70 days, respectively, from start of study treatment)"}],"references":[],"start_date":{"date":"2019-10-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial","url":"https://clinicaltrials.gov/study/NCT03801902"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/archon-1-nct03801902"}